Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

ARYx Therapeutics

Request full access

Pharmaceutical company focused on retrometabolic drug designing and improving the safety of oral therapies for chronic diseases

Fremont, United StatesFounded 1997Biotech & Life Sciences

About ARYx Therapeutics

ARYx Therapeutics, Inc. was a biopharmaceutical company founded in 1997 by Peter Milner, with its headquarters in Fremont, California. The company focused on developing a portfolio of internally discovered product candidates. Its business model was centered on its proprietary RetroMetabolic Drug Design technology, which aimed to create structurally unique molecules. This technology was designed to retain the efficacy of well-established, commercially successful drugs while metabolizing them through a safer pathway to avoid known adverse side effects.

The company's clinical development pipeline included several products. Naronapride (ATI-7505) was a prokinetic agent for treating various gastrointestinal disorders. Tecarfarin (ATI-5923) was developed as an oral anticoagulant. Budiodarone (ATI-2042) was an oral anti-arrhythmic agent for atrial fibrillation, and ATI-9242 was an agent for treating schizophrenia and other psychiatric disorders. The company went public with an IPO on November 8, 2007. Over its lifetime, ARYx Therapeutics raised a total of $226 million in funding.

Despite its product pipeline, the company faced significant challenges. In October 2010, ARYx received a notice of non-compliance from NASDAQ for failing to meet the minimum market capitalization requirement. Subsequently, in December 2010, its stock listing was transferred from the NASDAQ Global Market to the NASDAQ Capital Market. The company's situation worsened, and in March 2011, ARYx Therapeutics announced it would be closing its operations. This decision was attributed to a delay by the FDA in providing guidance on a critical trial design for its gastrointestinal drug, naronapride, which led to the withdrawal of a planned financing from investors. The company laid off its remaining executives, who were then hired as consultants in a final attempt to move forward. Ultimately, the company terminated all employees in 2010 and became a shell company before liquidating in May 2013. The liquidation was not expected to provide any cash return to stockholders, with assets going to secured creditors.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2007

ARYx Therapeutics in the Fremont ecosystem

Live from Dealroom

The ARYx Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later13 investors entered at this stage

  • OrbiMed
  • MPM BioImpact
  • Merlin Biomed
  • Nomura Phase4 Ventures
  • Itochu Technology Ventures
  • Montreux Equity Partners
  • Scottish Widows
  • JAFCO
  • Novel Bioventures
  • ATEL Ventures
  • Ascent Biomedical Ventures
  • NEA
  • Lighthouse Capital Partners
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about ARYx Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See ARYx Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.